A Safer Path for Diabetic Eye Disease
Millions of people with diabetes face a serious risk: damage to the blood vessels in the back of the eye. When these vessels become abnormal and leak, it can lead to vision loss. For years, doctors have used laser treatment to seal these vessels. More recently, powerful injections that block abnormal vessel growth have become a mainstay of care.
But what happens when you combine both? New research suggests that using injections together with laser treatment may offer a safer, more efficient path for people with proliferative diabetic retinopathy (PDR).
Proliferative diabetic retinopathy is a severe form of diabetic eye disease. It happens when the retina, the light-sensitive tissue at the back of the eye, grows new, fragile blood vessels. These vessels are weak and can bleed into the eye, causing floaters, blurred vision, or even severe vision loss.
It is a leading cause of blindness in working-age adults. Current treatments aim to stop these abnormal vessels from growing. The two main options are injections of a drug called ranibizumab, which blocks the vessel growth signal, and panretinal photocoagulation (PRP), a type of laser treatment that burns parts of the peripheral retina to reduce the drive for new vessel growth.
For a long time, doctors debated the best approach. Should they use injections alone? Or combine them with laser? This study helps answer that question.
A New Look at a Common Choice
The old way of thinking often pitted these two treatments against each other. Injections were seen as a newer, more targeted option. PRP was a well-established, but sometimes aggressive, laser procedure that could affect side vision.
But here's the twist: this research suggests they work better together than apart. The study found that combining ranibizumab injections with PRP led to better long-term control of the disease, with fewer treatments needed overall.
Think of it like managing a fire. The injection is like a targeted water spray that puts out the flames right away. The laser is like removing the flammable material around the fire so it has less fuel to spread. Using both can control the fire more effectively and prevent it from coming back.
How the Treatments Work Together
Ranibizumab works by blocking a protein called VEGF (vascular endothelial growth factor). In PDR, the eye makes too much VEGF, which signals the body to grow new, leaky blood vessels. The injection acts like a key that fits into a lock, blocking that signal and stopping the abnormal growth.
PRP, on the other hand, is a more direct approach. The laser creates tiny burns on the retina, reducing the area's oxygen demand. This lowers the overall signal for VEGF production. It’s a bit like turning down the thermostat in a room to stop the heater from working overtime.
When used together, the injection quickly calms the active disease, while the laser provides a lasting, structural change that keeps the disease in check over the long term.
What the Researchers Studied
The study looked back at 238 patients with PDR treated between 2019 and 2023. About half received ranibizumab injections alone. The other half received ranibizumab injections combined with PRP laser treatment.
Doctors tracked how much the abnormal blood vessels shrank (regressed) over two years. They also measured vision, the thickness of the central retina, and how many treatments and complications occurred.
The Results: Better Control, Fewer Procedures
After two years, the combination group had a much lower rate of active, abnormal blood vessels on the optic nerve. Only about 9% of patients in the combined group still had these vessels, compared to 23% in the injection-only group.
This doesn't mean this treatment is available yet.
Most importantly, vision and retinal thickness were the same in both groups. This means patients got the better disease control without losing any sight. The combination group also needed significantly fewer injections—about 11 on average, compared to 15 for the injection-only group.
They also had far fewer rescue treatments. Only 2.7% in the combination group needed extra laser treatment later, compared to 21.6% in the injection-only group. The rates of serious complications, like bleeding in the eye or needing surgery, were also much lower in the combination group.
What Experts Might Say
While the study doesn't include direct expert quotes, its findings align with a growing trend in ophthalmology: using combination therapy to improve long-term outcomes. The data strongly suggests that adding PRP to ranibizumab injections is an independent protective factor, meaning it actively reduces the risk of the disease not regressing.
If you or a loved one has proliferative diabetic retinopathy, this research offers hope for a more efficient treatment plan. It suggests that a combined approach could mean fewer trips to the clinic for injections and a lower risk of sight-threatening complications down the road.
However, this is not medical advice. Treatment decisions should always be made with a retinal specialist who can assess your individual case. Talk to your doctor about whether a combination therapy is right for you.
A Note on the Research
It is important to remember that this was a retrospective study. Researchers looked at data from past patient records rather than assigning treatments in a controlled, new trial. This type of study can show strong associations but cannot prove cause and effect with the same certainty as a prospective trial.
What Happens Next
The next step is to see these findings tested in larger, prospective studies. Researchers will likely investigate the optimal timing and number of laser treatments when combined with injections. As more data emerges, treatment guidelines for PDR may evolve to favor this combined approach, potentially improving care for millions of people with diabetes.
